Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charu Aggarwal

Showing results (101-110 of 170) with videos related to

Pageof 17
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2019
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)Charu Aggarwal, Mary W Redman, Primo N Lara, et al.
JAMA Network Open|July 15, 2025
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical TrialCharu Aggarwal, Alex Martinez-Marti, Margarita Majem, et al.
Clinical Lung Cancer|December 6, 2020
Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based TherapyLova Sun, Christiana W Davis, Wei-Ting Hwang, et al.
JCO Precision Oncology|February 16, 2019
Influence of <i>TP53</i> Mutation on Survival in Patients With Advanced <i>EGFR</i>-Mutant Non-Small-Cell Lung CancerCharu Aggarwal, Christiana W Davis, Rosemarie Mick, et al.
Scientific Reports|June 15, 2022
Development of a robust radiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first-line immunotherapyApurva Singh, Hannah Horng, Leonid Roshkovan, et al.
JCO Precision Oncology|July 15, 2026
EMBER-Lung: Electronic Medical Record Boosting Molecular Testing in Early-Stage Non-Small Cell Lung CancerWilldragon Wang, Dylan G Scholes, Alex C Watts, et al.
Head & Neck|August 15, 2019
The impact of treatment package time on locoregional control for HPV+ oropharyngeal squamous cell carcinoma treated with surgery and postoperative (chemo)radiationHann-Hsiang Chao, Caitlin A Schonewolf, Erik X Tan, et al.
International Journal of Radiation Oncology, Biology, Physics|October 22, 2023
Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint InhibitorsCole Friedes, Michelle Iocolano, Sang Ho Lee, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 19, 2018
Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural EffusionCharu Aggarwal, Andrew R Haas, Susan Metzger, et al.
Cancer Medicine|August 30, 2020
Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trialLaurie E Steffen McLouth, Fengmin Zhao, Taofeek K Owonikoko, et al.
Pageof 17

Showing results (101-110 of 170) with videos related to

Sort By:
Pageof 17
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2019
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)Charu Aggarwal, Mary W Redman, Primo N Lara, et al.
JAMA Network Open|July 15, 2025
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical TrialCharu Aggarwal, Alex Martinez-Marti, Margarita Majem, et al.
Clinical Lung Cancer|December 6, 2020
Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based TherapyLova Sun, Christiana W Davis, Wei-Ting Hwang, et al.
JCO Precision Oncology|February 16, 2019
Influence of <i>TP53</i> Mutation on Survival in Patients With Advanced <i>EGFR</i>-Mutant Non-Small-Cell Lung CancerCharu Aggarwal, Christiana W Davis, Rosemarie Mick, et al.
Scientific Reports|June 15, 2022
Development of a robust radiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first-line immunotherapyApurva Singh, Hannah Horng, Leonid Roshkovan, et al.
JCO Precision Oncology|July 15, 2026
EMBER-Lung: Electronic Medical Record Boosting Molecular Testing in Early-Stage Non-Small Cell Lung CancerWilldragon Wang, Dylan G Scholes, Alex C Watts, et al.
Head & Neck|August 15, 2019
The impact of treatment package time on locoregional control for HPV+ oropharyngeal squamous cell carcinoma treated with surgery and postoperative (chemo)radiationHann-Hsiang Chao, Caitlin A Schonewolf, Erik X Tan, et al.
International Journal of Radiation Oncology, Biology, Physics|October 22, 2023
Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint InhibitorsCole Friedes, Michelle Iocolano, Sang Ho Lee, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 19, 2018
Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural EffusionCharu Aggarwal, Andrew R Haas, Susan Metzger, et al.
Cancer Medicine|August 30, 2020
Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trialLaurie E Steffen McLouth, Fengmin Zhao, Taofeek K Owonikoko, et al.
Pageof 17